Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,470.00    50.00 (2.07%)
Bid:
2,466.00
Ask:
2,470.00
Spread: 4.00 (0.162%)
Market Cap: £7.93b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

21 Apr 2021 07:00

RNS Number : 0754W
Bunzl PLC
21 April 2021
 

21 April 2021

 

BUNZL Q1 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 31 December 2020.

 

Bunzl's diversified and resilient business model has delivered good overall growth against continuing pandemic-related challenges, with Group revenue in the first quarter up 5.4% at actual exchange rates and 10.4% at constant exchange rates. Acquisitions contributed revenue growth of 4.3% at constant exchange rates, while a greater number of trading days than the comparable period in 2020 further benefited revenue growth by 4.7%. Underlying revenue growth at constant exchange rates increased by 1.4%, in line with the Group's expectations. Group adjusted operating margin continued to be supported by demand for certain Covid-19 related products.

 

Within underlying revenue growth of 1.4%, sales of the top 8 Covid-19 related products, which are primarily own brand, contributed 6.4% of growth. This growth more than offset a 5.0% decline in revenue from other product sales. Good underlying revenue performance in North America and Rest of the World was driven by demand for Covid-19 related products, with certain category-specific pricing remaining elevated, and a continuation of the recovery in sales of other products. Continental Europe and UK & Ireland continued to be impacted by the effect of pandemic-related restrictions, particularly on foodservice and non-food retail segments.

 

The Group's guidance remains unchanged. At constant exchange rates, the Group continues to expect robust revenue growth in 2021 compared to the prior year, after excluding larger Covid-19 related orders which contributed approximately £550 million of revenue in 2020. A recovery in sales of other products is expected to be largely offset by a decline in smaller Covid-19 related orders, while recent acquisitions will further contribute to the Group's performance in 2021. After excluding larger Covid-19 related orders, the Group continues to expect good organic revenue growth in the first half of 2021 to be followed by a moderate decline in the second half. Group adjusted operating margin for the year is expected to return to a more historical level.

 

Commenting on today's results, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Now over a year on from the start of the pandemic I continue to thank our colleagues for their exceptional hard work supporting front line heroes and essential businesses through these extraordinary times. As activity starts to resume in some of our markets, it is with pride that I now see our teams increasingly supporting customers to reopen their businesses, many of which have been meaningfully impacted over the course of the pandemic. The resilience of the Bunzl model continues to be demonstrated by our ability to respond to changing customer needs and through our financial performance.

 

Looking ahead we are confident in the strength of our consistent and proven compounding strategy, supported by enhanced hygiene trends, our differentiated offering of sustainable and responsible solutions and acquisition momentum. We have announced three acquisitions in the year to date with the pipeline remaining active and a number of discussions ongoing."

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

David Allchurch

Martin Robinson

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBSGDSCUDDGBG
Date   Source Headline
29th Aug 201712:15 pmRNSDividend Declaration
29th Aug 20177:00 amRNSHalf-year Report
29th Aug 20177:00 amRNSAcquisition
15th Aug 201710:13 amRNSAdditional Listing
9th Aug 20172:56 pmRNSHolding(s) in Company
7th Aug 201712:09 pmRNSHolding(s) in Company
2nd Aug 20172:56 pmRNSHolding(s) in Company
1st Aug 201710:34 amRNSTotal Voting Rights
20th Jul 20177:00 amRNSAcquisition
14th Jul 20171:12 pmRNSDirector/PDMR Shareholding
5th Jul 20173:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20172:01 pmRNSTotal Voting Rights
3rd Jul 20179:50 amRNSHolding(s) in Company
3rd Jul 20179:00 amRNSDirector Declaration
28th Jun 20177:00 amRNSTrading Statement
6th Jun 20171:13 pmRNSDirector/PDMR Shareholding
2nd Jun 20173:51 pmRNSHolding(s) in Company
1st Jun 201710:26 amRNSTotal Voting Rights
24th May 20177:00 amRNSAcquisition
3rd May 20174:47 pmRNSDirector/PDMR Shareholding
3rd May 20174:42 pmRNSBlock listing Interim Review
2nd May 20174:21 pmRNSDirector/PDMR Shareholding
2nd May 20174:19 pmRNSDirector/PDMR Shareholding
2nd May 20173:35 pmRNSTotal Voting Rights
27th Apr 20175:38 pmRNSDirector/PDMR Shareholding
26th Apr 20179:54 amRNSAdditional Listing
19th Apr 20172:20 pmRNSResult of AGM
19th Apr 20177:00 amRNSTrading Statement
13th Apr 20171:56 pmRNSDirector/PDMR Shareholding
13th Apr 201710:21 amRNSAdditional Listing
11th Apr 20175:12 pmRNSDirector/PDMR Shareholding
7th Apr 20175:12 pmRNSDirector/PDMR Shareholding
6th Apr 20174:16 pmRNSDirector/PDMR Shareholding
4th Apr 20174:34 pmRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSAcquisition
3rd Apr 20179:43 amRNSTotal Voting Rights
28th Mar 201712:37 pmRNSDirector/PDMR Shareholding
28th Mar 20179:42 amRNSDirectorate Change
16th Mar 20174:28 pmRNSAnnual Financial Report
14th Mar 201711:01 amRNSDirector Declaration
6th Mar 20175:54 pmRNSDirector/PDMR Shareholding
6th Mar 20173:49 pmRNSHolding(s) in Company
3rd Mar 20173:38 pmRNSDirector/PDMR Shareholding
2nd Mar 20174:45 pmRNSDirector/PDMR Shareholding
2nd Mar 20172:10 pmRNSDirector/PDMR Shareholding
1st Mar 20174:27 pmRNSTotal Voting Rights
1st Mar 20177:00 amRNSAcquisition
27th Feb 20171:30 pmRNSDividend Declaration
27th Feb 20177:00 amRNSDirectorate Change
27th Feb 20177:00 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.